Bitte benutzen Sie diese Kennung, um auf die Ressource zu verweisen: http://doi.org/10.25358/openscience-10036
Autoren: Marx-Gross, Susanne
Kroell, Angelina
Wollschlaeger, Daniel
Schuster, Alexander K.
Riedl, Jana C.
Wasielica-Poslednik, Joanna
Pfeiffer, Norbert
Titel: Impact of cross-linking procedure on perioperative quality of life in keratoconus patients
Online-Publikationsdatum: 16-Feb-2024
Erscheinungsdatum: 2023
Sprache des Dokuments: Englisch
Zusammenfassung/Abstract: Background: To evaluate the effect of crosslinking (CXL) with riboflavin for keratoconus (KC) therapy on quality of life (QoL): comparison of keratoconus patients with and without treatment. Methods: Prospective monocentric study. We recruited patients with progressive KC and with stable disease. Patients with progressive disease received cross-linking treatment; patients with stable disease were monitored. We compared QoL in both groups over 6 months and detected the influence of cross-linking treatment on QoL. QoL was assessed by NEI-VFQ-25, EQ-5D 5L, and EQ-Visual analog scale (VAS). In the evaluation of the Nei VFQ, the subgroups LFVFS and LFSES were calculated. Results: We enrolled 31 eyes of 31 patients in the intervention group and 37 eyes of 37 patients in the control group. Medians with standard deviations (SD) were calculated. All QoL-tests showed equal scores at baseline in both groups. At V2, one day after the treatment, EQ-VAS (56.4), LFVFS (57.4), and EQ5D5L (0.59) were significantly reduced. At V3 (one week after treatment), all results returned to baseline level. LFSES was not affected by the treatment. It remained stable (V2 85.4, V3 84.3). Comparing the baseline scores with the follow-up scores at month 6, we found a significant increase in QoL in all tests in the intervention group. Otherwise, the quality of life in the control group did not change over time. Conclusions: Cross-linking led only to a short-term reduction in QoL. Although the treatment is painful for a few days, no effect on general quality of life LVSES has been demonstrated. QoL already returned to baseline after one week and the patients were not limited anymore.
DDC-Sachgruppe: 610 Medizin
610 Medical sciences
Veröffentlichende Institution: Johannes Gutenberg-Universität Mainz
Organisationseinheit: FB 04 Medizin
Veröffentlichungsort: Mainz
ROR: https://ror.org/023b0x485
DOI: http://doi.org/10.25358/openscience-10036
Version: Published version
Publikationstyp: Zeitschriftenaufsatz
Weitere Angaben zur Dokumentart: Scientific article
Nutzungsrechte: CC BY
Informationen zu den Nutzungsrechten: https://creativecommons.org/licenses/by/4.0/
Zeitschrift: Journal of Clinical Medicine
12
11
Seitenzahl oder Artikelnummer: 3833
Verlag: MDPI
Verlagsort: Basel
Erscheinungsdatum: 2023
ISSN: 2077-0383
DOI der Originalveröffentlichung: 10.3390/jcm12113833
Enthalten in den Sammlungen:DFG-491381577-G

Dateien zu dieser Ressource:
  Datei Beschreibung GrößeFormat
Miniaturbild
impact_of_crosslinking_proced-20240205155314422.pdf256.88 kBAdobe PDFÖffnen/Anzeigen